IGC Applauds Signing of Bipartisan Medical Marijuana and Cannabidiol Research Expansion Act December 7, 2022 Read More »
IGC Commences Phase 2 Clinical Trials Evaluating Drug Candidate IGC-AD1 for the Treatment of Agitation in Dementia From Alzheimer Disease December 1, 2022 Read More »
IGC Announces Issuance of Second Patent for the Treatment of Alzheimer’s Using THC September 21, 2022 Read More »
IGC Acquires Exclusive Rights for a Potential Alzheimer’s Drug Development Candidate June 21, 2022 Read More »
